197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab does not cross-react with TNF-␣, TNF-, TRAIL, or CD40 ligand (361).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [361]
Citations
Cites
Still being checked.
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationRANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 142
Self-citationSutjandra, L., Rodriguez, R. D., Doshi, S., Ma, M., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594240-000000000-00000 · Cited by 123
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
Gibiansky, L. V., Sutjandra, L., Doshi, S., Zheng, J., Sohn, W. Y., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2012) · Clinical Pharmacokinetics · doi:10.2165/11598090-000000000-00000 · Cited by 101
Cancer-related hypercalcemia and potential treatments
Almuradova, E., & Çiçin, İ. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1039490 · Cited by 83
Metadata
- Authors
- Elliott, R., Kostenuik, P., Chen, C., Kelley, M., Hawkins, N., Housman, J., McCabe, S., Mukku, V., Sullivan, J., & Dougall, W.
- Venue
- European Journal of Cancer Supplements
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 4
- Issue
- 12
- Pages
- 62
- ISSN
- 1359-6349 (ISSN-L)
- OpenAlex
- W2026115199
- Cited by
- 14
- References
- 0
- Citations by year
- 2023: 1 · 2021: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2012: 2
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- European Journal of Cancer Supplements (publishedVersion)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoclastogenesis, bone resorption, head and neck cancer, human papillomavirus, p16, tonsillar carcinoma, base of tongue cancer, smoking, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo. https://app.cochat.ai/papers/10.1016/s1359-6349(06)70202-6
- The paper
- Elliott, R., Kostenuik, P., Chen, C., Kelley, M., Hawkins, N., Housman, J., McCabe, S., Mukku, V., Sullivan, J., & Dougall, W. (2006). 197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo. European Journal of Cancer Supplements. https://doi.org/10.1016/s1359-6349(06)70202-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.